SCHEMBL20938186

SCHEMBL20938186

Nc1ncnc2c1c(CCc1ccccc1)cn2[C@@H]1O[C@H](CO)C[C@H]1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 4/20 0.45
▸ ABL1 P00519 2/20 0.44
▸ EGFR P00533 2/20 0.44
▸ ABL2 P42684 2/20 0.44
▸ SRC P12931 5/20 0.43
▸ METTL3 Q86U44 4/20 0.42
▸ PRMT5 O14744 2/20 0.42
▸ LCK P06239 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ TEK Q02763 1/20 0.41
▸ WDR77 Q9BQA1 1/20 0.41
▸ DOT1L Q8TEK3 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ GALR3 O60755 1/20 0.41
▸ S1PR4 O95977 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ S1PR1 P21453 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22912604 0.84 ADK (0.63) ADKABL1EGFRABL2SRC
SCHEMBL20916992 0.84 ADK (0.63) ADKABL1EGFRABL2SRC
SCHEMBL20938188 0.84 ADK (0.47) ADKMETTL3PRMT5DOT1LNPC1
SCHEMBL20917263 0.84 ADK (0.47) ADKMETTL3PRMT5DOT1LNPC1
SCHEMBL20938272 0.80 SRC (0.45) ADKABL1EGFRABL2SRC
SCHEMBL20938256 0.80 ADK (0.48) ADKABL1EGFRABL2SRC
SCHEMBL20917719 0.80 ADK (0.48) ADKABL1EGFRABL2SRC
SCHEMBL20938262 0.79 ADK (0.59) ADKMETTL3
SCHEMBL22912603 0.79 PRMT5 (0.48) ADKMETTL3PRMT5WDR77DOT1L
SCHEMBL20938333 0.79 ADK (0.46) ADKMETTL3PRMT5DOT1LNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections UNIVERSITEIT GENT (BE) 2021-07-27 — — US disclosed
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2021-01-28 — — US disclosed
WO-2019076633-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS UNIVERSITEIT GENT (BE) 2019-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072628-B2 Nucleoside analogues for the treatment of parasitic infections PNP, NUDT1, SAMHD1 ADK 109/4885ABL1 1044/4885EGFR 4884/4885
US-20210024566-A1 NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS PNP, NUDT1, SAMHD1 ADK 109/4885ABL1 1044/4885EGFR 4884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback